Hangzhou Yuanda Biopharmaceutical Co., Ltd. is a state-level high-tech enterprise specializing in biopharmaceutical technology and product development, production and sales. It is also a microecological preparation drug development and production enterprise in Zhejiang Province.

The company was founded in December 2004, with a registered capital of 40 million yuan and an area of 11.2 mu. In 2013, it joined China Yuanda Group and became its wholly-owned subsidiary. Adhering to the cultural values of "loyalty, simplicity, diligence and innovation," Hangzhou Yuanda has been pragmatic and innovative, and has successively won honorary titles such as "Healthy China·Leading Enterprise,""Excellent Backbone Enterprise,""Nomination Award for Quality Award of Hangzhou City People's Government,""Provincial Enterprise Research Institute," etc.

The company's leading product "Bifidobacterium quadruple viable tablets", a new microecological preparation, has independent invention patents, has entered the 2019 edition of the national medical insurance catalogue.

Focusing on the strategic goal of "becoming the most competitive enterprise in China in the field of digestion and metabolism and probiotic health," Hangzhou Yuanda has formulated clear realization paths in R & D innovation, production quality, marketing and investment and merger.
The company attaches great importance to academic research and has set up a professional R & D center. It has accumulated 25 invention patent applications and authorizations, including 8 authorized invention patents and 1 PCT international patent application. In line with the concept of young, professional and international talents, the company has set up a research and development team of more than 30 people, covering the cultivation of large varieties, new product development and new technology layout, and assisting the terminal academic promotion. With years of deep cultivation in the fields of digestion, metabolism and probiotics, Hangzhou Yuanda has accumulated a lot and established an "expert workstation" to build a higher-level R & D and innovation platform.
The company has modern bacterial powder, preparation and packaging production lines. On the existing basis, the capacity of the new production line will reach 1.58 billion tablets; the modern bacterial powder fermentation collection and preparation production base under construction can guarantee the capacity supply in the next 15 years. The company always adheres to the quality management concept of "one dose of medicine, two lives" and the quality policy of "integrity and reliability, full participation, traceability, improvement and innovation", carries out quality work, ensures product quality, and realizes continuous improvement and upgrading of quality management level.

In 2015, the company promoted the innovation and upgrading of its marketing model, achieved steady growth in sales performance, and maintained a compound growth rate of more than 30% every year. At present, it has four marketing channels, including Hospital Division, Retail Division, Primary Medical Division and E-commerce Division. In 2021, the marketing center will continue to focus on the real work, the progress, the implementation, and the goal of one billion yuan!

At the same time, the investment and merger in Hangzhou Yuanda's 2020-2025 strategic plan started smoothly. In August 2020, the Company successfully acquired Chongqing Taiping Pharmaceutical Co., Ltd., renamed Yuanda Biopharmaceutical (Chongqing) Co., Ltd., acquired the product line Misang, optimized the product portfolio of microecological preparations, and provided strong support for the realization of strategic objectives.

Under the guidance of the cultural concept of "loyalty, simplicity, diligence and innovation", Hangzhou Yuanda attaches great importance to talents and advocates hard work. It promotes the working principles of "training in battle, grinding in the middle","filling the locomotive with oil, making the horse run faster" and "letting the incentive rush to the pressure" throughout the company, and strives towards the goal of 1 billion yuan with the attitude of "three eyes" to help realize the overall strategy of the enterprise!